WARNING Clostridioides difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including CLEOCIN PHOSPHATE and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
Because CLEOCIN PHOSPHATE therapy has been associated with severe colitis which may end fatally, it should be reserved for serious infections where less toxic antimicrobial agents are inappropriate, as described in the INDICATIONS AND USAGE section. It should not be used in patients with nonbacterial infections such as most upper respiratory tract infections.
C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use.
Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
Use: Labeled indications
- INDICATIONS AND USAGE CLEOCIN PHOSPHATE products are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria.
Full indications and usage US FDA label
INDICATIONS AND USAGE CLEOCIN PHOSPHATE products are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. CLEOCIN PHOSPHATE products are also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate.
Because of the risk of antibacterial drug-associated pseudomembranous colitis, as described in the BOXED WARNING, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin.
Indicated surgical procedures should be performed in conjunction with antibacterial drug therapy. CLEOCIN PHOSPHATE is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae, other streptococci (except E. faecalis), and Staphylococcus aureus.
Skin and skin structure infections caused by Streptococcus pyogenes, Staphylococcus aureus, and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms.
Septicemia caused by Staphylococcus aureus, streptococci (except Enterococcus faecalis), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CLEOCIN PHOSPHATE and other antibacterial drugs, CLEOCIN PHOSPHATE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy.
In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Contraindications
CONTRAINDICATIONS This drug is contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin.
US FDA labelDosing: Adult
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION If diarrhea occurs during therapy, this antibacterial drug should be discontinued (see WARNING box). Clindamycin phosphate IM administration should be used undiluted. Clindamycin phosphate IV administration should be diluted (see Dilution for IV use and IV infusion rates below). Adults Parenteral (IM or IV Administration) Serious infections due to aerobic gram-positive cocci and the more susceptible anaerobes (NOT generally including Bacteroides fragilis, Peptococcus species and Clostridium species other than Clostridium perfringens): 600–1200 mg/day in 2, 3 or 4 equal doses.
More severe infections, particularly those due to proven or suspected Bacteroides fragilis, Peptococcus species, or Clostridium species other than Clostridium perfringens: 1200–2700 mg/day in 2, 3 or 4 equal doses. For more serious infections, these doses may have to be increased. In life-threatening situations due to either aerobes or anaerobes these doses may be increased.
Doses of as much as 4800 mg daily have been given intravenously to adults. (see Dilution for IV use and IV Infusion Rates section below). Single intramuscular injections of greater than 600 mg are not recommended. Alternatively, drug may be administered in the form of a single rapid infusion of the first dose followed by continuous IV infusion as follows: Table 2: Serum Clindamycin Levels Maintained, Rapid Infusion Rate and Maintenance Infusion Rate To maintain serum clindamycin levels Rapid infusion rate Maintenance infusion rate Above 4 mcg/mL 10 mg/min for 30 min 0.75 mg/min Above 5 mcg/mL 15 mg/min for 30 min 1.00 mg/min Above 6 mcg/mL 20 mg/min for 30 min 1.25 mg/min Pediatric Patients 1 month of age to 16 years Parenteral (IM or IV) Administration 20 to 40 mg/kg/day in 3 or 4 equal doses.
The higher doses would be used for more severe infections. Clindamycin should be dosed based on total body weight regardless of obesity. As an alternative to dosing on a body weight basis, pediatric patients may be dosed on the basis of square meters body surface: 350 mg/m 2 /day for serious infections and 450 mg/m 2 /day for more severe infections.
Parenteral therapy may be changed to oral CLEOCIN PEDIATRIC ® Flavored Granules (clindamycin palmitate hydrochloride) or CLEOCIN HCl ® Capsules (clindamycin hydrochloride) when the condition warrants and at the discretion of the physician. In cases of β-hemolytic streptococcal infections, treatment should be continued for at least 10 days.
Pediatric Patients less than 1 month The recommended dosage is 15 to 20 mg/kg/day in 3 to 4 equal doses. (see Table 3) regarding the dosing regimen for pediatric patients with post-menstrual age (PMA) less than or equal to 32 weeks, or greater than 32 weeks to less than or equal to 40 weeks. Table 3: Dosing Regimens for Pediatric Patients with PMA less than or equal to 32 weeks, or greater than 32 weeks to less than or equal to 40 weeks PMA (weeks) Dose (mg/kg) Dosing Interval (hours) PMA: Post-Menstrual age Less than or equal to 32 5 8 Greater than or equal to 32 to less than or equal to 40 7 8 Dilution for IV use and IV Infusion Rates The concentration of clindamycin in diluent for infusion should not exceed 18 mg per mL.
Infusion rates should not exceed 30 mg per minute. The usual infusion dilutions and rates are as follows: Dose Diluent Time 300 mg 50 mL 10 min 600 mg 50 mL 20 min 900 mg 50–100 mL 30 min 1200 mg 100 mL 40 min Administration of more than 1200 mg in a single 1-hour infusion is not recommended. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Dilution and Compatibility Physical and biological compatibility studies monitored for 24 hours at room temperature have demonstrated no inactivation or incompatibility with the use of CLEOCIN PHOSPHATE Sterile Solution (clindamycin phosphate) in IV solutions containing sodium chloride, glucose, calcium or potassium, and solutions containing vitamin B complex in concentrations usually used clinically. No incompatibility has been demonstrated with the antibacterial drugs cephalothin, kanamycin, gentamicin, penicillin or carbenicillin.
The following drugs are physically incompatible with clindamycin phosphate: ampicillin sodium, phenytoin sodium, barbiturates, aminophylline, calcium gluconate, and magnesium sulfate. The compatibility and duration of stability of drug admixtures will vary depending on concentration and other conditions. Physico-Chemical Stability of Diluted Solutions of CLEOCIN PHOSPHATE Room Temperature 6, 9 and 12 mg/mL (equivalent to clindamycin base) in dextrose injection 5%, sodium chloride injection 0.9%, or Lactated Ringers Injection in glass bottles, demonstrated physical and chemical stability for at least 16 days at 25°C.
Refrigeration 6, 9 and 12 mg/mL (equivalent to clindamycin base) in dextrose injection 5%, sodium chloride injection 0.9%, or Lactated Ringers Injection in glass bottles, demonstrated physical and chemical stability for at least 32 days at 4°C. IMPORTANT: This chemical stability information in no way indicates that it would be acceptable practice to use this product well after the preparation time.
Good professional practice suggests that compounded admixtures should be administered as soon after preparation as is feasible.
Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Pediatric
Pediatric use (US label) US FDA label
Pediatric Use When CLEOCIN PHOSPHATE Sterile Solution is administered to the pediatric population (birth to 16 years) appropriate monitoring of organ system functions is desirable (see CLINICAL PHARMACOLOGY and DOSAGE AND ADMINISTRATION).
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use Clinical studies of clindamycin did not include sufficient numbers of patients age 65 and over to determine whether they respond differently from younger patients. However, other reported clinical experience indicates that antibacterial drug-associated colitis and diarrhea (due to Clostridioides difficile) seen in association with most antibacterial drugs occur more frequently in the elderly (>60 years) and may be more severe.
These patients should be carefully monitored for the development of diarrhea. Pharmacokinetic studies with clindamycin have shown no clinically important differences between young and elderly subjects with normal hepatic function and normal (age-adjusted) renal function after oral or intravenous administration.
Dosage forms
Philippines
- Capsule: 150 mg, 300 mg
- ) solution for injection: 150 mg/mL (300 mg/2 mL, 150 mg/mL (300 mg/2 mL/600 mg/4 mL, 150 mg/mL (600 mg/4 mL
- Solution for injection: 150 mg/mL, 300 mg/2 mL
- Topical gel: 10 mg/g
- Topical solution: 10 mg/mL, 20 mg/mL
- ) topical solution: 10 mg/mL
- Gel: 10 mg/g
- Granule for oral solution: 75 mg/5 mL
- Soft gelatin capsule: 100 mg
- Solution for iv infusion: 150 mg/mL
and 1 more forms; see the products table.
Registered products in the Philippines
203 products registered with the Food and Drug Administration (FDA) Philippines list Clindamycin as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Clindamycin as Hydrochloride (1 product) · Clindamyn (as hydrochloride) (1 product). Products registered under these spellings are included in the table and marked.
All registered products203
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
Abanxl-300Clindamycin (as hydrochloride) | 300 mg CapsuleAlu/Alu Blister Pack (Box of 10’s) | Rx | XL Laboratories Pvt. Ltd.India | Dynasty PharmaceuticalsImporter: Ambica International Corporation | DRP-1267 | Dec 16, 2030 | |
Acce-MycinClindamycin (as phosphate) | 150 mg/mL (300 mg/2mL / 600 mg/4mL) Solution for Injection (I.M./I.V.)Type 1 Clear Glass Ampoule x 2 mL (Box of 5's) Type 1 Clear Glass Ampoule x 5 mL (Box of 5's) | Rx | Maxitech Pharma (Pvt.) Ltd.Pakistan | Accesspoint International Trading, Inc. | DRP-14203 | Aug 27, 2030 | |
Acresil 150Clindamycin (as hydrochloride) | 150 mg CapsuleIn individual box of blister pack x 10's Box of 100's | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DRP-879 | Sep 30, 2027 | |
Acresil 300Clindamycin (as hydrochloride) | 300 mg CapsuleBlister Pack x 10’s (Box of 100’s) | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DRP-546 | Nov 29, 2027 | |
AfrendaClindamycin (as phosphate) | 150mg/mL Solution for Injection4 mL in 5 mL USP Type I amber glass ampoule (Box of 5 ampoules in PVC Tray) | Rx | Makcur Laboratories LimitedIndia | Afree Pharmaceutical Distribution CorpImporter: Afree Pharmaceutical Distribution Corp. | DRP-14096 | Jun 20, 2028 | |
AkneclinClindamycin (as phosphate) | 10 mg/g (1 % w/w) Topical GelWhite, Opaque LDPE Plastic Tube X 5 g Box of 1 's; White, Opaque LDPE Plastic Tube X 15 g Box of 1 's; White, Opaque LDPE Plastic Tube X 30 g Box of 1 's | Rx | Zee Laboratories LimitedIndia | EON PHARMATEK INC. | DR-XY43741 | Nov 24, 2029 | |
AmaxinClindamycin (as hydrochloride) | 300 mg CapsuleAlu/ PVC Blister Pack x 10’s (Box of 30’s and 100’s) | Rx | Fredun Pharmaceutical LimitedIndia | Maraki Pharma Co.Importer: AMB HK Enterprises Inc. | DRP-13378-01 | Feb 8, 2028 | |
AmbiclinClindamycin (as hydrochloride) | 150 mg CapsuleAlu/Clear PVC Blister Pack x 10’s (Box of 100’s) | Rx | Brawn Laboratories LimitedIndia | Ambica International Corporation | DRP-4917 | Nov 13, 2028 | |
Amsocyn-300Clindamycin (as Phosphate) | 150 mg/mL (300 mg/2 mL) Solution for Injection (I.M./I.V.)Type I clear colorless borosilicate glass ampoule x 2 mL (net content) (Box of 10's) | Rx | North China Pharmaceutical Co., Ltd.China | Amson PharmaceuticalsImporter: Nueva Sunshine Phils., Inc. | DRP-10375-01 | Sep 16, 2031 | |
Amsocyn-600Clindamycin (as Phosphate) | 150 mg/mL (600 mg/4 mL) Solution for InjectionType I Clear Colorless Borosilicate Glass Ampoule x 4 mL (net content) (Box of 10's) | Rx | North China Pharmaceutical Co., Ltd.China | Amson PharmaceuticalsImporter: Nueva Sunshine Phils. Inc. | DRP-10374-01 | Sep 16, 2031 | |
AndimycinClindamycin (as hydrochloride) | 300 mg CapsuleAlu/PVC Clear Blister Pack x 10's (Box of 30's and 100's) | Rx | Bauch Phils. Laboratories Inc.Philippines | LO-AR Pharmaceutical Co., Inc. | DRP-6945 | Dec 9, 2026 | |
AnerocinClindamycin (as hydrochloride) | 150 mg CapsuleBlister Pack x 10's Box of 100's | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Aldril Pharmaceuticals, Inc. | DR-XY23377 | Oct 2, 2027 | |
AnerocinClindamycin (as hydrochloride) | 150 mg CapsuleBlister Pack x 10s (Box of 100s) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Aldril Pharmaceuticals, Inc. | DRP-15993 | Oct 2, 2027 | |
300 mg CapsuleClear PVC/Alu Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Aldril Pharmaceuticals, Inc. | DRP-7619 | Jun 22, 2031 | ||
AnticiemClindamycin (as phosphate) | 150 mg/mL Solution for Injection (IM/IV)Type I Flint Glass Ampoule x 2 mL (Box of 10's); 5 mL Type I Flint Glass Ampoule x 4 mL (net content) (Box of 5's) | Rx | Samrudh Pharmaceuticals Pvt. Ltd.India | I.E. Medica, IncTrader: Alvita Pharma Pvt. Ltd. | DRP-14172 | Jul 13, 2028 | |
BanbaktClindamycin (as phosphate) | 100 mg Vaginal SuppositoryPVC/PE Strip x 3's (Box of 3's) | Rx | Kusum Healthcare Pvt. Ltd.India | Kusum Healthcare Private Limited Branch Office | DR-XY48255 | Aug 3, 2027 | |
Brill-Clinda 4Clindamycin (as phosphate) | 150 mg/mL Solution for Injection (IM/IV)Clear Colorless USP Type I Glass Ampoule x 4mL (Box of 10's) | Rx | Kwality Pharmaceuticals Ltd.India | Rcbrilliant Pharma Corp.Importer: Pharma-Surrey International, Inc. | DRP-6334-02 | Sep 9, 2030 | |
CinoClindamycin (as hydrochloride) | 150 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | CSPC Ouyi Pharmaceutical Co. Ltd.China | AMB HK Enterprises Inc. | DRP-17377 | Nov 25, 2030 | |
CinoClindamycin (as hydrochloride) | 300 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | CSPC Ouyi Pharmaceutical Co. Ltd.China | AMB HK Enterprises Inc. | DRP-17376 | Nov 25, 2030 | |
ClamynexClindamycin (as hydrochloride) | 300mg CapsuleAlu/Alu Blister Pack x 10 (Box of 100’s) | Rx | The IBN Sina Pharamceutical Industry Ltd.Bangladesh | D'Conner PharmaImporter: Euro Generics International Phils., Inc. | DR-XY49803 | Sep 22, 2031 | |
ClimaxinClindamycin (as Hydrochloride) | 300 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | Flamingo Pharmaceuticals Ltd.India | Labmate Pharma Inc.Importer: Hexagon Pharmaceuticals | DRP-546-02 | Nov 29, 2027 | |
Clin-GenClindamycin (as hydrochloride) | 150 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | New Myrex Laboratories, Inc.Philippines | — | DRP-2434 | Sep 3, 2030 | |
Clin-GenClindamycin (as hydrochloride) | 300 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | New Myrex Laboratories, Inc.Philippines | — | DRP-2433 | Sep 3, 2030 | |
ClinagenClindamycin (as Hydrochloride) | 300 mg CapsuleAlu / PVC Clear Blister Pack x 10's (Box of 30's, 50's & 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-16906-02 | Aug 15, 2030 | |
ClinamakClindamycin (as Phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (IM/IV)Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Hillcross Prime, Inc. | DRP-10927 | Dec 17, 2031 | |
ClinametClindamycin (as phosphate) | 150 mg/mL Solution for Injection (IM/IV)4 mL Type I clear glass ampoule in plastic tray (Box of 5’s) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Pro-Jectable Pharmaceuticals, Inc.Importer: PhilRx Pharma Inc. | DRP-12933-03 | Nov 4, 2027 | |
ClinasanClindamycin (as Phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (IM/IV)Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Sanimed Pharmaceuticals Inc.Importer: Hillcross Prime, Inc. | DRP-10927-01 | Dec 17, 2031 | |
ClinawiseClindamycin (as Phosphate) | 150 mg/ mL (600 mg/4 mL) Solution for injection (IM/IV)Type I Amber Glass Ampoule x 5 mL (Box of 5’s) | Rx | Makcur Laboratories LimitedIndia | Medwise, Inc.Importer: HillCross Prime, Inc. | DRP-10927-02 | Dec 17, 2026 | |
ClinbacClindamycin (as phosphate) | 150 mg/mL Solution for Injection (IM/IV)Clear Colorless USP Type I Glass Ampoule x 4mL (Box of 10's) | Rx | Kwality Pharmaceuticals Ltd.India | Pharma-Surrey International, Inc. | DRP-6334 | Sep 9, 2030 | |
ClinbacClindamycin (as phosphate) | 300 mg/2mL Solution for Injection (IM/IV)USP Type I Colorless Glass Ampoule x 2mL (Box of 10's) | Rx | Kwality Pharmaceuticals Ltd.India | Pharma-Surrey International, Inc. | DRP-5845 | Dec 4, 2029 | |
ClincidamClindamycin (as hydrochloride) | 300 mg CapsuleAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | XL Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-1267-04 | Mar 16, 2031 | |
Clinda-SClindamycin (as hydrochloride) | 150 mg CapsuleAlu / PVC Blister Pack x 10's (Box of 100's) | Rx | Scheele Laboratories Phils., Inc.Philippines | — | DRP-018 | Mar 15, 2031 | |
Clinda-SClindamycin (as hydrochloride) | 300 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | Scheele Laboratories Phils., Inc.Philippines | — | DRP-3708 | Mar 6, 2031 | |
ClindabasClindamycin (as phosphate) | 150 mg/mL Solution for Injection (IM/IV)USP Type I Amber glass ampoule in PVC plastic tray x 2 mL (Box of 10's) and x 4 mL (Box of 10's) | Rx | Friends Pharma (Pvt.) Ltd.Pakistan | Raquel-Abbas Pharmaceuticals & General Merchandise | DRP-17145 | Oct 7, 2031 | |
ClindacareClindamycin (as phosphate) | 150 mg/mL (300 mg/2 mL) Solution for Injection (I.M./I.V.)USP Type I Clear and Colorless Glass Ampoule x 2 mL (Net Content) (Box of 1's and Box of 10's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Applied Pharmaceutical Distribution IncImporter: Euro-Care Products Philippines | DRP-10761 | Nov 16, 2036 | |
Clindacare 600Clindamycin (as phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (IM/IV)Type I glass ampoule x 4 mL in 5 mL (Box of 1's). | Rx | Furen Pharmaceutical Group Co., Ltd..China | Euro-care Products Philippines | DRP-15428 | Jul 8, 2029 | |
ClindacentClindamycin Phosphate | 150mg/mL (600mg/4mL) Solution For Injection (Iv/Im)Type I Amber glass ampoule x 4 mL (Box of 10's) | Rx | Swiss Parenterals Ltd.India | Central West Medicale, Inc. | DRP-18428 | Jul 8, 2031 | |
ClindacinClindamycin (as hydrochloride) | 300 mg CapsuleBlister Pack x 10's (Box of 30's and 100's) | Rx | Interphil Laboratories, Inc.Philippines | — | DRP-1455 | Dec 4, 2028 | |
ClindaconClindamycin (as Phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (IM/IV)Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | D' Conner PharmaImporter: Hillcross Prime, Inc. | DRP-10927-03 | Dec 17, 2031 | |
ClindacureClindamycin (as phosphate) | 150 mg/mL Solution for Injection (IM/IV)2 mL and 4 mL Type I clear glass ampoule in plastic tray (Box of 10's) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Cyden Medicale Trading Inc.Importer: PhilRx Pharma Inc. | DRP-12933-01 | Nov 4, 2027 | |
ClindaferClindamycin (as phosphate) | 150 mg/mL (300 mg/2mL) Solution for Injection (IM/IV)Type I Clear Glass Ampoule x 2 mL (Box of 5's) | Rx | Maxitech Pharma (Pvt.) Ltd.Pakistan | Ferjan Philippines Inc.Importer: Accesspoint International Trading Inc. | DRP-14203-03 | Jul 20, 2028 | |
ClindagenClindamycin (as hydrochloride) | 300 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | Interphil Laboratories, Inc.Philippines | Nutramedica Inc. | DRP-1455-04 | Dec 4, 2028 | |
ClindaGetClindamycin (as phosphate) | 150 mg/mL (600 mg/4 mL) Solution For Injection (IM/IV)USP Type I Clear Glass ampoule with red ring snap off x 4 mL (Box of 5's) | Rx | Venus Remedies Ltd.India | 2MG Incorporated | DRP-18283 | Jun 8, 2031 | |
ClindagoldClindamycin (as hydrochloride) | 150 mg CapsuleAlu / PVC Blister Pack x 10's (Box of 100's) | Rx | Scheele Laboratories Phils., Inc.Philippines | Jickstar Pharma Inc. | DRP-018-02 | Jul 30, 2031 | |
ClindagoldClindamycin (as hydrochloride) | 300 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | Scheele Laboratories Phils., Inc.Philippines | Jickstar Pharma Inc. | DRP-3708-01 | Jul 6, 2031 | |
ClindalClindamycin (as hydrochloride) | 150 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | HIZON LABORATORIES, INC.Philippines | Trader: ONE PHARMA MARKETING INC. | DR-XY28449 | Mar 25, 2028 | |
ClindalClindamycin (as phosphate) | 150 mg/mL Solution for Injection (I.M./I.V.)USP Type I Amber Glass Ampoule x 2 mL and 4 mL (Box of 10's) | Rx | Union Korea Pharm Co., Ltd. FKorea | One Pharma Marketing Inc. | DR-XY33407 | Sep 30, 2029 | |
ClindalClindamycin (as hydrochloride) | 300 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | Hizon Laboratories, Inc.Philippines | Trader: One Pharma Marketing Inc. | DR-XY24058 | Jun 3, 2028 | |
ClindalevClindamycin (as Phosphate) | 150 mg/mL (300 mg/2 mL) Solution for Injection (IM/IV)2 mL USP Type I Clear Glass Ampoule (Box of 10's) | Rx | Vesco Pharmaceutical Company LimitedThailand | HLM Pharmaceutical Inc.Importer: Euro-Care Products Philippines | DRP-6948-04 | Nov 19, 2031 | |
ClindalonClindamycin (as Phosphate) | 150 mg/mL Solution for Injection (IM/IV)USP Type I Clear Glass Ampoule x 2 mL (Box of 1's, 5's and 10's); USP Type I Clear Glass Ampoule x 4 mL (Box of 1's, 5's and 10's) | Rx | Norris Medicines LimitedIndia | Vivilon Pharmaceuticals Inc.Importer: Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd. | DRP-5676-03 | Oct 29, 2029 | |
ClindamClindamycin (as phosphate) | 150 mg /mL Solution for Injection (IM/IV)Clear Colorless USP Type I Glass Ampoule x 4mL (Box of 10's) | Rx | Kwality Pharmaceuticals Ltd.India | Philind PharmaceuticalsImporter: Pharma-Surrey International, Inc. | DRP-6334-03 | Sep 9, 2030 | |
ClindamClindamycin (as phosphate) | 300 mg /2 mL Solution for Injection (IM/IV)USP Type I Colorless Glass Ampoule x 2mL (Box of 10’s) | Rx | Kwality Pharmaceuticals Ltd.India | Philind PharmaceuticalsImporter: Pharma-Surrey International, Inc. | DRP-5845-02 | Dec 4, 2029 | |
ClindanavClindamycin (as phosphate) | 150 mg/mL (300 mg/2 mL) Solution for Injection (IM/IV)USP Type I clear glass ampoule x 2 mL (Box of 1's) | Rx | Scott-Edil Pharm Pharmacia LimitedIndia | JNC Pharmaceuticals CorporationImporter: Pharmakon Biotec Inc. | DRP-15462-02 | Aug 1, 2029 | |
ClindanavClindamycin (as phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (IM/IV)USP Type I clear glass ampoule x 4 mL (Box of 1's) | Rx | Scott-Edil Pharmacia Limited(H.P.) India | JNC Pharmaceuticals CorporationImporter: Pharmakon Biotec Inc. | DRP-15463-03 | Aug 1, 2029 | |
ClindanovaClindamycin (As Hydrochloride) | 300 mg CapsuleAlu/Alu Blister Pack of 10's (Box of 100's) | Rx | Saga Lifesciences LimitedIndia | Medinova Pharmaceutical, Inc | DRP-13525 | Mar 6, 2028 | |
ClindaphilClindamycin (as phosphate) | 150 mg/mL Solution For Injection (I.M./I.V.)2 mL and 4 mL Type I clear glass ampoule in plastic tray (Box of 10's) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc. | DRP-12933 | Nov 4, 2027 | |
CLINDAPREMClindamycin (as phosphate) | 150 mg/ mL Solution for Injection (IM/IV)2 mL and 4 mL Type I clear glass ampoule in plastic tray (Box of 5’s) | Rx | Hebei TIancheng Pharmaceutical Co., Ltd.China | Premier Pharmaceuticals Marketing Corp.Importer: PhilRx Pharma Inc. | DRP-12933-06 | Nov 4, 2027 | |
ClindapremClindamycin (as hydrochloride) | 300 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 100's; Box of 30's) | Rx | Saga Lifesciences LimitedIndia | Premier Pharmaceuticals Marketing Corp.Importer: Medinova Pharmaceutical Inc. | DRP-13525-02 | Mar 6, 2028 | |
Clindaprim 600Clindamycin (as phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (IM/IV)USP Type I clear glass ampoule x 4 mL (Box of 1's) | Rx | Scott-Edil Pharm Pharmacia LimitedIndia | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-15463-02 | Aug 1, 2029 | |
ClindareneClindamycin (as phosphate) | 150 mg/mL (300 mg/2 mL) Solution for Injection (I.M./I.V.)USP Type I Glass Ampoule with red and blue ring on neck x 2 mL (Box of 1's) | Rx | United Biotech (P) LimitedIndia | Neo-Care PhilippinesImporter: Triple Tact Import & Export Corp. | DRP-4324-02 | Sep 28, 2027 | |
ClindareneClindamycin (as phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (I.M./I.V.)USP Type I Clear Glass Ampoule with white and blue ring on the neck x 4 mL in 5 mL capacity (Box of 1 's) | Rx | United Biotech (P) LimitedIndia | Neo-Care PhilippinesImporter: Triple Tact Import & Export Corp.. | DRP-4355-02 | Sep 28, 2027 | |
Clindasal-600Clindamycin (as phosphate) | 150 mg/mL Solution for Injection (IM/IV)USP Type I clear glass ampoule x 4 mL (Box of 1's in PVC plastic tray) | Rx | Shree Anand Life Sciences, Ltd.India | Medinova Pharmaceutical Inc. | DRP-49357 | Mar 18, 2030 | |
ClindasanClindamycin (as phosphate) | 150 mg/mL Solution for Injection (I.M./I.V.)USP Type I Clear Glass Ampoule x 2 mL (Box of 1's, 5's and 10's); USP Type I Clear Glass Ampoule x 4 mL (Box of 1's, 5's and 10's) | Rx | Norris Medicines LimitedIndia | I.E. Medica, Inc.Importer: Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd. | DRP-5676-02 | Oct 29, 2029 | |
ClindasaphClindamycin (as hydrochloride) | 150 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 10 Blister Packs x 10 Capsules) | Rx | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-13684 | Oct 17, 2030 | |
Clindasaph-300Clindamycin (as hydrochloride) | 300 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 10 Blister Packs x 10 capsules) | Rx | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-12761 | Oct 17, 2030 | |
Clindasaph-600Clindamycin (As Phosphate) | 150mg/mL Solution for Injection (I.M./I.V.)USP Type I clear glass ampoule in plastic tray x 2 mL (300 mg/2 mL; Box of 10's) and 4 mL (600 mg/4 mL; Box of 10's) | Rx | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-10998 | Dec 31, 2026 | |
Clindasaph-B300Clindamycin (as Hydrochloride) | 300 mg CapsuleAlu/Clear PVC Blister Pack x 10’s (Box of 100’s) | Rx | Belco PharmaIndia | Ollen Pharma Trading Inc. | DRP-18128 | May 7, 2031 | |
Clindasaph-G300Clindamycin (as Hydrochloride) | 300 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100’s) | Rx | Global Pharma Healthcare Private LimitedIndia | Nelpa Lifesciences, Inc. | DRP-18064 | Apr 30, 2031 | |
ClindasaveClindamycin (as phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (IM/IV)USP Type I Clear Glass Ampoule x 4 mL in a plastic tray (Box of 10’s) | Rx | North China Pharmaceutical Co., Ltd (New Preparation Branch Factory)China | Savelink Pharma and Trading Co.Importer: AGlobal Care, Inc. | DRP-13816-02 | Jul 27, 2031 | |
ClindasephClindamycin (as phosphate) | 150 mg / mL Solution for Injection (IM/IV)Type I Flint Glass Ampoule x 2 mL (Box of 10's); 5 mL Type I Flint Glass Ampoule x 4 mL (net content) (Box of 5's) | Rx | Samrudh Pharmaceuticals Pvt. Ltd.India | Neo-Care PhilippinesImporter: Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd. | DRP-14172-01 | Jul 13, 2028 | |
ClindasephClindamycin (as phosphate) | 150 mg/mL Solution for Injection (l.M./1.V.)USP Type I clear glass ampoule x 2 mL (Box of 1's, and 10's); USP Type I clear glass ampoule x 4 mL (Box of 1's, and 10's) | Rx | Norris Medicines LimitedIndia | Neo-Care PhilippinesImporter: MedEthix, Inc.Trader: Alvita Pharma Pvt. Ltd. | DRP-5676-04 | Oct 29, 2029 | |
ClindasheenClindamycin (as phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (IM/IV)USP Type I clear glass ampoule x 4 mL (Box of 1’s) | Rx | Scott-Edil Pharmacia LimitedIndia | Farmacia SheenaImporter: Pharmakon Biotec Inc. | DRP-15463-01 | Aug 1, 2029 | |
ClindasonClindamycin (as Phosphate) | 150 mg/mL Solution for Injection (IM/IV)4 mL Low Borosilicate Glass Ampoule (Box of 5’s) | Rx | CSPC Ouyi Pharmaceutical Co. Ltd.China | Amson PharmaceuticalsImporter: Sahar International Trading Inc.Trader: Betterway Pharmaceutical Group (HK) Limited | DRP-6466-01 | Jul 8, 2029 | |
ClindaspeedClindamycin (as hydrochloride) | 300 mg CapsuleAluminum Foil Strip x 10's (Box of 100's) | Rx | Interphil Laboratories, Inc.Philippines | Speed Med Pharmaceuticals Inc. | DRP-1455-07 | Dec 4, 2028 | |
ClindatecClindamycin (as phosphate) | 150 mg/mL (300 mg/2 mL) Solution for Injection (I.M./I.V.)USP Type I Glass Ampoule with red and blue ring on neck x 2 mL (Box of 1's) | Rx | United Biotech (P) LimitedIndia | Triple Tact Import & Export Corp. | DRP-4324 | Sep 28, 2027 | |
CLINDATECClindamycin (as phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (I.M./I.V.)USP Type I Clear Glass Ampoule with white and blue ring on neck x 4 mL in 5 mL Box of 1 's | Rx | United Biotech (P) LimitedIndia | TRIPLE TACT IMPORT & EXPORT CORP. | DRP-4355 | Sep 28, 2027 | |
ClindavestClindamycin (as Phosphate) | 150 mg/mL (300 mg/2 mL) Solution for Injection (IM/IV)2 mL USP Type I Clear Glass Ampoule (Box of 10's) | Rx | Vesco Pharmaceutical Company LimitedThailand | Asianmeds, Inc.Importer: Euro-Care Products Philippines | DRP-6948-06 | Jan 25, 2032 | |
Clindavest 600Clindamycin (as Phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (I.M./I.V.)Type I Clear, colorless glass vial x 4 mL (net content) (Box of 1's) | Rx | Vesco Pharmaceutical Company LimitedThailand | Asianmeds, Inc.Importer: Euro-Care Products Philippines | DRP-8749-01 | Feb 21, 2030 | |
Clindavest 600Clindamycin (as phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (IM/IV)Type I transparent glass ampoule x 4 mL in 5 mL (Box of 1's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Asianmeds Inc. | DRP-15427 | Jul 8, 2029 | |
ClindavintClindamycin (as phosphate) | 150 mg/mL Solution for Injection (IM/IV)2 mL and 4 mL Type I clear glass ampoule in plastic tray (Box of 5’s and 10’s) | Rx | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Vintel Med EnterprisesImporter: Philrx Pharma Inc. | DRP-12933-04 | Nov 4, 2027 | |
ClindaxinClindamycin (as hydrochloride) | 150 mg CapsuleAlu/Deep Red PVC Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Zeutica, Inc. | DR-XY35083 | Oct 28, 2028 | |
ClindaxinClindamycin (as Hydrochloride) | 300 mg CapsuleAlu/Red PVDC Blister Pack x 10's Box of 100's | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Zeutica, Inc. | DR-XY36476 | Aug 13, 2029 | |
Clindazet 150Clindamycin (as hydrochloride) | 150 mg CapsuleAlu/Clear PVC Blister Pack x 10’s (Box of 10 Blister Packs x 10 Capsules) | Rx | Genom Biotech Pvt. Ltd.India | Roymed PharmaceuticalImporter: Nelpa Lifesciences, Inc. | DRP-13684-01 | Oct 17, 2030 | |
Clindex-600Clindamycin (as phosphate) | 150 mg/mL Solution for Injection (IM/IV)4 mL in 5 mL USP Type I amber glass ampoule (Box of 5's ampoules in PVC Tray) | Rx | Makcur Laboratories LimitedIndia | Sonchel Pharma DistributorsImporter: Afree Pharmaceutical Distribution Corp. | DRP-14096-01 | Jun 20, 2028 | |
ClindiaClindamycin (as hydrochloride) | 300 mg CapsuleClear PVC/Alu Blister Pack x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | The Cathay Drug Co., Inc.Trader: Aldril Pharmaceuticals, Inc. | DRP-7619-01 | Jun 22, 2031 | |
ClindollenClindamycin (as Phosphate) | 150 mg/mL Solution for Injection (I.M./I.V.)USP Type I clear glass ampoule in plastic tray x 2 mL (300mg/2mL) (Box of 10's); USP Type I clear glass ampoule in plastic tray x 4 mL (600mg/4mL) (Box of 10's) | Rx | Kilitch Drugs (India) Ltd.India | Ollen Pharma Trading Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-10998-01 | Dec 31, 2026 | |
Clindollen-B150Clindamycin (as Phosphate) | 150 mg/mL Solution For Injection (IM/IV)Type I Clear Glass Ampoule x 2 mL and 4 mL in PVC Tray (Box of 5's and 10's) | Rx | Belco PharmaIndia | Ollen Pharma Trading Inc. | DRP-18972 | Oct 8, 2031 | |
ClinmedClindamycin (as phosphate) | 150 mg/mL Solution for Injection (I.M./I.V.)USP Type I clear clear glass ampoule x 2 mL (Box of 1's, 5's and 10's); USP Type I clear glass ampoule x 4 mL (Box of 1's, 5's and 10's) | Rx | Norris Medicines LimitedIndia | Medhaus Pharma, IncorporatedImporter: Medethix, Inc.Trader: Alvita Pharma Pvt. Ltd. | DRP-5676 | Oct 29, 2029 | |
ClinmicapClindamycin (as hydrochloride) | 300 mg CapsuleAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | XL Laboratories Pvt. Ltd.India | K Pharma Medical Corp.Importer: Ambica International Corporation | DRP-1267-06 | Feb 9, 2031 | |
ClinmynClindamycin Phosphate | 150 mg/mL Solution for Injection (I.M./I.V.)2 mL and 4 mL Amber Colored Ampoule in PVC tray (Box of 10’s) | Rx | Samjin Pharm. Co., Ltd.Republic of Korea | Medbridge, Inc. | DR-XY43601 | Aug 8, 2027 | |
ClinovexClindamycin (as phosphate) | 150 mg/mL (300 mg/2 mL) Solution for Injection (IM/IV)USP Type I clear glass ampoule x 2 mL (Box of 1's) | Rx | Scott-Edil Pharmacia LimitedIndia | Northmed Pharma and Medical Supplies DistributionImporter: Pharmakon Biotec Inc. | DRP-15462-01 | Aug 1, 2029 | |
Clinsea-300Clindamycin (as phosphate) | 300 mg/2 mL Solution for Injection (IM/IV)USP Type I Colorless Glass Ampoule x 2 mL (Box of 10's) | Rx | Kwality Pharmaceuticals Ltd.India | Seapharma International, Inc.Importer: Pharma-Surrey International, Inc. | DRP-5845-01 | Dec 4, 2029 | |
Clinsea-600Clindamycin (as phosphate) | 150 mg/mL Solution for Injection (IM/IV)Clear Colorless USP Type I Glass Ampoule x 4 mL (Box of 10's) | Rx | Kwality Pharmaceuticals Ltd.India | Seapharma International, Inc.Importer: Pharma-Surrey International, Inc. | DRP-6334-01 | Jul 30, 2031 | |
ClintamClindamycin(as phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection(I.M./I.V.)USP Type I Clear Glass Ampoule with white and blue ring on neck x 4 mL in 5 mL (Box of 1's) | Rx | United Biotech Pvt. Ltd.India | Tamiga Pharmaceuticals SupplyImporter: Triple Tact Import & Export Corp. | DRP-4355-04 | Sep 28, 2027 | |
ClintopClindamycin Hydrochloride | 150 mg CapsuleAlu/PVC Blister Pack x10's (Box of 10 blister packs x 10 capsules) | Rx | Fredun Pharmaceuticals LimitedIndia | Amb HK Enterprises Inc. | DRP-13609 | Mar 16, 2028 | |
ClintopClindamycin hydrochloride | 150 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Baroque Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-17320 | Nov 14, 2030 | |
ClintopClindamycin (as hydrochloride) | 300 mg CapsuleAlu/PVC Blister Pack x 10's | Rx | Fredun Pharmaceuticals LimitedIndia | Amb HK Enterprises Inc.Trader: N/A | DRP-14915 | Feb 8, 2029 | |
ClintopClindamycin hydrochloride | 300 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | Baroque Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-17321 | Nov 14, 2030 | |
Clintrix 600Clindamycin (as Phosphate) | 150 mg/mL (600 mg/4mL) Solution for Injection (IM/IV)Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Madecs Pharma CorporationImporter: Hillcross Prime, Inc. | DRP-10927-04 | Dec 17, 2031 | |
Corsin-300Clindamycin (as phosphate) | 150 mg/mL (300 mg/2 mL) Solution for Injection (I.M./I.V.)USP Type I Glass Ampoule with red and blue ring on the neck x 2 mL (Box of 1's) | Rx | United Biotech (P) LimitedIndia | Greencore Pharma Inc.Importer: Triple Tact Import & Export Corp.. | DRP-4324-01 | Sep 28, 2027 | |
Corsin-600Clindamycin (as phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (I.M./I.V.)USP Type I Clear Glass Ampoule with white and blue ring on the neck x 4 mL in 5 mL Box of 1 's | Rx | United Biotech (P) LimitedIndia | GREENCORE PHARMA INC.Importer: TRIPLE TACT IMPORT & EXPORT CORP. | DRP-4355-01 | Sep 28, 2027 | |
Dalacin CClindamycin (as hydrochloride) | 150 mg CapsuleBlister Pack of 10's (Box of 100's) | Rx | PT. Pfizer IndonesiaIndonesia | Importer: Pfizer, Inc. | DRP-1954 | Mar 13, 2028 | |
Dalacin CClindamycin (as phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (IV/IM)USP Type I Glass Ampoule x 5mL (net content: 2mL & 4mL) (Box of 1’s) | Rx | Pfizer Manufacturing BelgiumBelgium | Importer: Pfizer, Inc. | DRP-1952 | Jun 19, 2029 | |
Dalacin CClindamycin (as hydrochloride) | 300 mg CapsuleBlister Pack of 10's (Box of 100's) | Rx | PT. Pfizer IndonesiaIndonesia | Importer: Pfizer, Inc. | DRP-1953 | Mar 13, 2028 | |
Dalacin CClindamycin (as Palmitate Hydrochloride) | 75mg/5mL Granules for Oral SolutionAmber Glass Bottle x 60mL (Box of 1's) | Rx | Interphil Laboratories, Inc.Philippines | Trader: Pfizer, Inc. | DRP-1951 | Jul 17, 2027 | |
DalactinClindamycin (as Hydrochloride) | 150 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's); Alu/Clear PVC Blister Pack 10's (Box of 100's) | Rx | Drugmaker's Laboratories Inc.Philippines | — | DRP-5681 | May 3, 2028 | |
DalaferClindamycin (as Hydrochloride) | 300 mg CapsuleAlu/PVC Clear Blister Pack x 10's (Box of 30's, 50's and 100's) | Rx | Azarias Pharmaceutical Laboratories, Inc.Philippines | Ferma Drug Enterprises | DRP-16906-03 | Aug 15, 2030 | |
DalamaxClindamycin (as hydrochloride) | 300 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | Interphil Laboratories, Inc.Philippines | Medchoice Women's Health (MCWH), Inc. | DRP-1455-02 | Dec 4, 2028 | |
DalamedClindamycin (as hydrochloride) | 300 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | Flamingo Pharmaceuticals Ltd.India | Trumed PharmaceuticalsImporter: Hexagon Pharmaceuticals | DRP-546-04 | Nov 29, 2027 | |
DalamycinClindamycin (as phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (IM/IV)USP Type I Clear Colorless Glass Ampoule x 4 mL in a plastic tray (Box of 10’s) | Rx | North China Pharmaceutical Co., LtdChina | Aglobal Care, Inc. | DRP-13816 | Jul 27, 2031 | |
DalasaveClindamycin (as phosphate) | 150 mg/mL (300 mg / 2mL) Solution for Injection (IM/IV)Type I Clear Glass Ampoule x 2 mL (Box of 5's) | Rx | Maxitech Pharma (Pvt.) Ltd.Pakistan | Savelink Pharma and Trading Co.Importer: Accesspoint International Trading Inc. | DRP-14203-01 | Jul 20, 2028 | |
DalasaveClindamycin (as phosphate) | 150 mg/mL (600mg/4mL) Solution for Injection (I.M./I.V.)Type I Clear Glass Ampoule x 5 mL (Box of 5's) | Rx | Maxitech Pharma (Pvt.) Ltd.Pakistan | Savelink Pharma And Trading CoImporter: Accesspoint International Trading Inc. | DRP-14203-06 | Aug 27, 2030 | |
DalincClindamycin (as phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (IM/IV)Type I Clear Colorless Glass Ampoule x 5 mL in PVC Tray (Box of 5's) | Rx | Cisen Pharmaceutical Co., Ltd.China | Greencore Pharma, Inc. | DRP-14871 | Jan 26, 2029 | |
DyclinClindamycin (as Phosphate) | 150mg/mL Solution for Injection (IM/IV)Type I Clear Glass Vial x 2 mL with Rubber Stopper and Yellow Flip-off Seal (Box of 10's) | Rx | Yung Shin Pharm. Ind. Co., Ltd- Taichung Youth FactoryR.O.C | Pharma King DistributorImporter: Yung Shin (Philippines), Inc. | DRP-1039-02 | Oct 25, 2027 | |
DYMYZNClindamycin (as Hydrochloride) | 300 mg CapsuleAlu/PVC Clear Blister Pack x 10's (Box of 30's, 50's & 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-16906 | Aug 15, 2030 | |
DynacinClindamycin (as Phosphate) | 150mg/mL Solution for Injection (IM/IV)Type I Clear Glass Vial x 2mL with Rubber Stopper and Yellow Flip-off Seal (Box of 10's) | Rx | Yung Shin Pharm. ind. Co., Ltd. - Taichung Youth FactoryChina | Dynasty PharmaceuticalsImporter: Yung Shin (Philippines), Inc. | DRP-1039-01 | Oct 25, 2027 | |
DynacinClindamycin (as hydrochloride) | 300 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Y.S.P. Industries (M) Sdn. Bhd.Malaysia | Dynasty PharmaceuticalsImporter: Yung Shin (Philippines), Inc. | DRP-7835-01 | Feb 24, 2031 | |
Dynacin 600Clindamycin (as Phosphate) | 150 mg/mL Solution for Injection (IM/IV)2 mL and 4 mL Type I clear glass ampoule in plastic tray (Box of 10’s) | Rx | Hebei Tiancheng Pharmaceutical Co., LtdChina | Dynasty PharmaceuticalsImporter: Philrx Pharma Inc. | DRP-12933-05 | Nov 4, 2027 | |
EuromycinClindamycin (as Phosphate) | 150 mg/mL (300 mg/2 mL) Solution for Injection (IM/IV)2 mL USP Type I Clear Glass Ampoule (Box of 10's) | Rx | Vesco Pharmaceutical Company LimitedThailand | Euro-Care Products Philippines | DRP-6948 | Mar 23, 2031 | |
Euromycin 600Clindamycin (as Phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (I.M./I.V.)Type I clear, colorless glass vial x 4 mL (net content) (Box of 1's) | Rx | Vesco Pharmaceutical Company LimitedThailand | Euro-Care Products Philippines | DRP-8749 | Feb 21, 2030 | |
GidacynClindamycin (as Phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (IM/IV)Type I Amber Glass Ampoule x 5 mL (Box of 5's) | Rx | Makcur Laboratories LimitedIndia | Gijun Trading Inc.Importer: Hillcross Prime, Inc | DRP-10927-05 | Dec 17, 2026 | |
Gidimycin 300Clindamycin (as phosphate) | 150 mg/mL (300 mg/2 mL) Solution for Injection (I.M./I.V.)USP Type I Glass Ampoule with red and blue ring on neck x 2 mL (Box of 1's) | Rx | United Biotech Pvt. Ltd.India | Gdmed Pharma DistributorImporter: Triple Tact Import & Export Corp. | DRP-4324-06 | Sep 28, 2027 | |
Gidimycin 600Clindamycin (as phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (I.M./I.V.)USP Type I Clear Glass Ampoule with white and blue ring on neck x 4 mL in 5 mL (Box of 1's) | Rx | United Biotech Pvt. Ltd.India | GDMed Pharma DistributorImporter: Triple Tact Import & Export Corp. | DRP-4355-06 | Sep 28, 2027 | |
IndacinClindamycin (as phosphate) | 10 mg/g (1% w/w) Topical GelOpaque white polyethylene tube with opaque white elongated nozzle and opaque white polypropylene cap x 10 g (Box of l’s) | Rx | Interphil Laboratories, Inc.Philippines | — | DRP-12261 | Jul 5, 2027 | |
IndaxClindamycin (as phosphate) | 150 mg/mL Solution for injection (I.M./I.V.)Type I Clear Glass Ampoule x 2 mL (Box of 10's) in PVC Tray | Rx | Mackur Laboratories LimitedIndia | Seapharma International, Inc. | DRP-15742 | Sep 11, 2029 | |
IndimaxClindamycin (as hydrochloride) | 300 mg CapsuleAlu/Alu Blister Pack of 10’s (Box of 10’s) | Rx | XL Laboratories Pvt. Ltd.India | All-Bio Pharma, Inc.Importer: Ambica International Corporation | DRP-1267-01 | Feb 9, 2037 | |
KlinbacClindamycin (as phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (IM/IV)Type I Clear Colorless Glass Ampoule in 2mL and 4mL (net content) [Box of 5's] | Rx | North China Pharmaceutical Co., Ltd.China | Endure Medical Inc.Importer: Singapore Genebio, Inc. | DR-XY43154 | Dec 12, 2029 | |
KlindaroneClindamycin (as Phosphate) | 150 mg/mL (300 mg/2 mL) Solution for Injection (I.M./I.V.)USP Type I clear and colorless glass ampoule x 2 mL (net content) (Box of 1's and 10's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Asianmeds, Inc.Importer: Euro-Care Products Philippine | DRP-10761-01 | Nov 16, 2031 | |
Klindarone 600Clindamycin (as Phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (IM/IV)Type I glass ampoule x 4 mL in 5 mL (Box of 1's) | Rx | Furen Pharmaceutical Group Co., Ltd.China | Asianmeds, Inc.Importer: Euro-care Products Philippines | DRP-15428-01 | Jul 8, 2029 | |
KlindaverClindamycin (as phophate) | 150 mg/mL Solution for IV Infusionype I glass ampoule x 4 mL (Box of 1's) | Rx | Osel Ilac San ve Tic A.S.Turkey | Accesspoint International Trading Inc.Importer: Accesspoint International Trading, Inc. | DRP-14105 | Jun 22, 2028 | |
KlindexClindamycin (as hydrochloride) | 150 mg CapsuleAluminum Strip Foil x 10's (Box of 100s) | Rx | RV Lifesciences LimitedIndia | UNILAB, Inc.Trader: Ultratech India Limited | DR-XY42493 | Sep 2, 2028 | |
KlindexClindamycin (as hydrochloride) | 150 mg CapsuleBlister pack x 10's (Box of 100's) | Rx | Amherst Laboratories, Inc.Philippines | UNILAB, Inc.Trader: Ritemed Phils., Inc. | DRP-2678-03 | May 25, 2027 | |
KlindexClindamycin (as hydrochloride) | 300 mg CapsuleAluminum Strip Foil x 10's (Box of 100's) | Rx | RV Lifesciences LimitedIndia | UNILAB, Inc.Trader: Ultratech India Limited | DR-XY42492 | Sep 2, 2028 | |
KlindexClindamycin (as hydrochloride) | 300 mg CapsuleBlister pack x 10's (Box of 100's) | Rx | Amherst Laboratories, Inc.Philippines | UNILAB, Inc.Trader: Ritemed Phils., Inc. | DRP-2640-03 | May 25, 2027 | |
KlinfarClindamycin (as phosphate) | 150 mg/mL (300 mg/2mL) Solution for Injection (IM/IV)USP Type I clear glass ampoule x 2 mL (Box of 1's) | Rx | Scott-Edil Pharm Pharmacia LimitedIndia | Pharmakon Biotec Inc. | DRP-15462 | Aug 1, 2029 | |
KlinfarClindamycin (as phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (IM/IV)USP Type I clear glass ampoule x 4 mL (Box of 1's) | Rx | Scott-Edil Pharm Pharmacia LimitedIndia | Pharmakon Biotec Inc. | DRP-15463 | Aug 1, 2029 | |
KlinvyrClindamycin (as phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (IM/IV)USP Type I Clear Colorless Glass Ampoule x 4 mL in a plastic tray (Box of 10’s) | Rx | North China Pharmaceutical Co., LtdChina | Solvire Life IncorporatedImporter: Aglobal Care, Inc. | DRP-13816-03 | Jul 27, 2031 | |
KlinzurClindamycin (as hydrochloride) | 300 mg CapsuleAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Magbro Healthcare Pvt. LtdIndia | Pharmakon Biotec Inc. | DRP-14521 | Sep 28, 2028 | |
KylezineClindamycin (as hydrochloride) | 300 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | New Myrex Laboratories, Inc.Philippines | TGP Pharma Inc. | DRP-2433-01 | Jul 11, 2031 | |
Macrodal 300Clindamycin (as Hydrochloride) | 300 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | J.M. Tolmann Laboratories, Inc.Philippines | Vamsler Phils. Inc. | DRP-15459-01 | Sep 11, 2027 | |
Marzyn 600Clindamycin (as Phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (I.M./I.V.)Type I clear, colorless glass vial x 4 mL (net content) (Box of 1's) | Rx | Vesco Pharmaceutical Company LimitedThailand | MDB Pharma TradingImporter: Euro-Care Products Philippines | DRP-8749-02 | Feb 21, 2030 | |
Mycin-CClindamycin (as phosphate) | 150 mg/mL Solution for Injection (IM/IV)USP Type I clear glass ampoule x 4 mL in a plastic tray (Box of 5's) | Rx | Med Biopharm Pvt. Ltd.India | Euroasia Pharmaceuticals, Inc.Importer: Pors Pharma Trading | DRP-17087-01 | Dec 17, 2029 | |
MyesurClindamycin (as phosphate) | 150 mg/mL (300 mg/2 mL) Solution for Injection (I.M./I.V.)USP Type I Clear Glass Ampoule x 2 mL (Box of 10's) | Rx | Makcur Laboratories LimitedIndia | Pharma-Surrey International, Inc. | DRP-16036 | Oct 18, 2029 | |
NoneClindamycin (as phosphate) | 10 mg/g (1% w/w) Topical GelAluminum Collapsible Tube x 10 g | Rx | Agio Pharmaceuticals LimitedIndia | Ambica International Corporation | DRP-3134 | Dec 3, 2031 | |
NoneClindamycin (as phosphate) | 150 mg / mL Solution for Injection (IM/IV)4 mL in 5 mL USP Type I amber glass ampoule (Box of 5 ampoule in PVC Tray) | Rx | Makcur Laboratories LimitedIndia | Vintel Med EnterprisesImporter: Afree Pharmaceutical Distribution Corp. | DRP-14096-04 | Jun 20, 2028 | |
NoneClindamycin (as hydrochloride) | 150 mg CapsuleAlu/PVC coated PVDC Clear Blister x 10's (Box of 100's) | Rx | Am-Europharma CorporationPhilippines | United Laboratories, Inc.Trader: Ritemed Phils., Inc. | DR-XY47120 | Dec 1, 2030 | |
NoneClindamycin (as hydrochloride) | 150 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | PT. Pfizer IndonesiaIndonesia | Philusa CorporationImporter: Pfizer, Inc. | DRP-1954-02 | Mar 13, 2028 | |
NoneClindamycin (as Hydrochloride) | 150 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | Amherst Laboratories, Inc.Philippines | Trader: Ritemed Phils., Inc. | DRP-2678 | May 25, 2027 | |
NoneClindamycin (as hydrochloride) | 150 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 30's); Alu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | TGP PHARMA, INC. | DRP-5681-01 | May 3, 2028 | |
NoneClindamycin (as hydrochloride) | 150 mg CapsuleIn individual box of blister pack x 10’s (Box of 100’s) | Rx | Flamingo Pharmaceuticals Ltd.India | Qualifirst Health, Inc.Importer: Hexagon Pharmaceuticals | DRP-879-02 | Sep 30, 2027 | |
NoneClindamycin (as phosphate) | 150 mg/mL (300 mg/2mL) Solution for Injection (IM/IV)Type I Clear Glass Ampoule x 2 mL (Box of 5's) | Rx | Maxitech Pharma (Pvt.) Ltd.Pakistan | Reta DrugImporter: Accesspoint International Trading Inc. | DRP-14203-04 | Jul 20, 2028 | |
NoneClindamycin (as phosphate) | 150 mg/mL (600 mg/4mL) Solution for Injection (I.M./I.V.)Type I Clear Glass Ampoule x 5 mL (Box of 5's) | Rx | Maxitech Pharma (Pvt.) Ltd.Pakistan | Reta DrugImporter: Accesspoint International Trading, Inc. | DRP-14203-05 | Aug 27, 2030 | |
NoneClindamycin (as phosphate) | 150 mg/mL Solution for Injection (IM/IV)4 mL in 5 mL USP Type I amber glass ampoule (Box of 5 ampoules in PVC Tray) | Rx | Makcur Laboratories LimitedIndia | Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-14096-02 | Jun 20, 2028 | |
NoneClindamycin (as Phosphate) | 150 mg/mL Solution for Injection (IM/IV)4 mL in 5 mL USP Type I amber glass ampoule (Box of 5 ampoules in PVC Tray) | Rx | Makcur Laboratories LimitedIndia | Bliss Pharma Distribution and Consultancy Corp.Importer: Afree Pharmaceutical Distribution Corp. | DRP-14096-03 | Jun 20, 2028 | |
NoneClindamycin (as phosphate) | 150 mg/mL Solution for Injection (IM/IV)4 mL in 5 mL USP Type I amber glass ampoule (Box of 5 ampoules in PVC Tray) | Rx | Makcur Laboratories LimitedIndia | Reta DrugImporter: Afree Pharmaceutical Distribution Corp. | DRP-14096-05 | Jun 20, 2028 | |
NoneClindamycin (as Hydrochloride) | 150mg CapsuleAlu/PVC Blister Pack x 10's (box of 100's) | Rx | J.M. Tolmann Laboratories, Inc.Philippines | — | DRP-9620 | Sep 10, 2027 | |
NoneClindamycin (as phosphate) | 150mg/mL (300mg/2mL) Solution for Injection (IM/IV)Type I Clear Glass Ampoule x 2mL (Box of 5's) | Rx | Maxitech Pharma (Pvt.) Ltd.Pakistan | Rexmed Pharmaceutical SalesImporter: Accesspoint International Trading Inc. | DRP-14203-02 | Jul 20, 2028 | |
NoneClindamycin (as Hydrochloride) | 300 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | Pascual Laboratories, Inc.Philippines | Pharex Health Corporation | DR-XY33745 | Nov 20, 2027 | |
NoneClindamycin (as hydrochloride) | 300 mg CapsuleAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | XL Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-1267-03 | Mar 12, 2031 | |
NoneClindamycin (as hydrochloride) | 300 mg CapsuleAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | XL Laboratories Pvt. Ltd.India | International Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-1267-07 | Feb 9, 2031 | |
NoneClindamycin (as hydrochloride) | 300 mg CapsuleAlu/Alu Blister Pack x 10's Box of 30's & 100's) | Rx | Saga Lifesciences LimitedIndia | Qualifirst Health Inc.Importer: Medinova Pharmaceutical Inc. | DRP-13525-01 | Mar 6, 2028 | |
NoneClindamycin (as hydrochloride) | 300 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | Interphil Laboratories, Inc.Philippines | Neodrug Inc. | DRP-1455-03 | Dec 4, 2028 | |
NoneClindamycin (as hydrochloride) | 300 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | Interphil Laboratories, Inc.Philippines | Rose Pharmacy, Incorporated | DRP-1455-05 | Dec 4, 2028 | |
NoneClindamycin (as hydrocloride) | 300 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | Interphil Laboratories, Inc.Philippines | St. Joseph Drugstore | DRP-1455-06 | Dec 4, 2028 | |
NoneClindamycin (as hydrochloride) | 300 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | Interphil Laboratories, Inc.Philippines | South Star Drug | DRP-1455-08 | Dec 4, 2028 | |
NoneClindamycin (as hydrochloride) | 300 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | PT. Pfizer IndonesiaIndonesia | Philusa CorporationImporter: Pfizer, Inc. | DRP-1953-02 | Mar 13, 2028 | |
NoneClindamycin (as hydrochloride) | 300 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | Amherst Laboratories, Inc.Philippines | Trader: Ritemed Phils., Inc. | DRP-2640 | May 25, 2027 | |
NoneClindamycin (as hydrochloride) | 300 mg CapsuleAlu/White PVC/PVDC Blister Pack x 10's (Box of 30's) | Rx | Sandoz s.r.l.Romania | Watsons Personal Care Stores (Philippines), Inc.Importer: Sandoz Philippines Corporation | DRP-3712-03 | Oct 23, 2028 | |
PeldacynClindamycin (as phosphate) | 150 mg/mL Solution for Injection (I.M./I.V.)USP Type I Amber Glass Ampoule x 2 mL n Plastic Tray (Box of 1’s); USP Type I Amber Glass Ampoule x 2 mL in Plastic Tray (Box of 10’s); USP Type I Amber Glass Ampoule x 4 mL in Plastic Tray (Box of 1’s); USP Type I Amber Glass Ampoule x 4 mL in Plastic Tray (Box of 10’s) | Rx | Samjin Pharmaceutical Co., Ltd.Republic of Korea | Natrapharm Inc. | DR-XY41979 | Apr 29, 2031 | |
PeldacynClindamycin (as hydrochloride) | 300 mg CapsuleAlu/White PVC/PVDC Blister Pack x 10's (Box of 30's) | Rx | Sandoz S.r.l.Romania | Natrapharm, Inc.Importer: Sandoz Philippines Corporation | DRP-3712-02 | Oct 23, 2028 | |
PorsclindaClindamycin (as phosphate) | 150 mg/mL Solution for Injection (IM/IV)USP Type I clear glass ampoule x 2 mL and 4 mL in a plastic tray (Box of 5's) | Rx | Med Biopharm Pvt. Ltd.India | Pors Pharma Trading | DRP-17087 | Dec 17, 2029 | |
300 mg CapsulePVC/Alu Blister Pack x 10's (Box of 100's) | Rx | Flamingo Pharmaceuticals Ltd.India | Scheeling, Inc.Importer: Hexagon Pharmaceuticals | DRP-546-01 | Nov 29, 2027 | ||
PromeclinClindamycin (as hydrochloride) | 300 mg CapsuleAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | XL Laboratories Pvt. Ltd.India | Providencia Medica Inc.Importer: Ambica International Corporation | DRP-1267-02 | Dec 16, 2030 | |
ProviclinClindamycin | 300 mg CapsuleAlu/PVC Blister pack of 10's (Box of 100's) | Rx | Rhydburg Pharmaceuticals LtdIndia | Providencia Medica Inc.Trader: N/A | DRP-19050 | Oct 21, 2031 | |
RabamycinClindamycin (as Phosphate) | 150 mg/mL Solution for Injection (IM/IV)4 mL Low Borosilicate Glass Ampoule (Box of 5's) | Rx | CSPC Ouyi Pharmaceutical Co. Ltd.China | Sahar International Trading Inc.Trader: Betterway Pharmaceutical Group (HK) Limited | DRP-6466 | Jul 8, 2029 | |
RapmycinClindamycin (as Hydrochloride) | 300 mg CapsuleAlu/PVC Clear Blister Pack x 10's (Box of 30's, 50's & 100's) | Rx | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-16906-01 | Aug 15, 2030 | |
RobecrenClindamycin (as hydrochloride) | 300 mg CapsuleAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | XL Laboratories Pvt. Ltd.India | RSG Pharma TradingImporter: Ambica International Corporation | DRP-1267-08 | Feb 9, 2031 | |
Rojan-CClindamycin (as hydrochloride) | 300 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | Scheele Laboratories Phils., Inc.Philippines | Rojanzar Pharmacy | DRP-3708-03 | Jul 20, 2031 | |
Rouxindal-300Clindamycin (as phosphate) | 150 mg/mL (300 mg/2 mL) Solution for Injection (I.M./I.V.)USP Type I Glass Ampoule with red and blue ring on the neck x 2 mL Box of 1's | Rx | United Biotech (P) LimitedIndia | ELLEBASY MEDICALE TRADINGImporter: TRIPLE TACT IMPORT & EXPORT CORP. | DRP-4324-03 | Sep 28, 2027 | |
Rouxindal-600Clindamycin (as phosphate) | 150 mg/mL (600 mg/4 mL) Solution for Injection (I.M./I.V.)USP Type I Clear Glass Ampoule with white and blue ring on the neck x 4 ml in 5 mL Box of 1 's | Rx | United Biotech (P) LimitedIndia | LABMATE PHARMA INC.Importer: TRIPLE TACT IMPORT & EXPORT CORP. | DRP-4355-03 | Sep 28, 2027 | |
RovymycinClindamycin (as phosphate) | 150 mg/mL (600 mg/4 mL) Solution for InjectionType I clear colorless borosilicate glass ampoule x 4 mL (net content) (Box of 10's) | Rx | North China Pharmaceutical Co., Ltd.China | Nueva Sunshine Phils., Inc. | DRP-10374 | Sep 16, 2031 | |
SkindalClindamycin (as Hydrochloride) | 300 mg CapsuleAlu/PVC Blister pack x 10's (Box of 30's); Alu/PVC Blister pack x 10's (Box of 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | — | DRP-803 | Jan 9, 2029 | |
SOSClindamycin (as Phosphate) | 1 % (10 mg / mL) Topical Solution10 mL Roll-on Clear Glass Bottle Bottle of 1's; 3 mL Roll-on Clear Glass Bottle Bottle of 1's | Rx | Diamond Laboratories, Inc.Philippines | Tobie Pharma Inc. | DRP-7296 | Nov 21, 2031 | |
StrepcinClindamycin (as Hydrochloride) | 150 mg CapsuleAlu/Clear PVC Blister pack x 10's (Box of 30's) | Rx | Drugmaker's Laboratories, Inc.Philippines | Phil Pharmawealth, Inc. | DRP-5681-02 | May 3, 2028 | |
StrepcinClindamycin (as Hydrochloride) | 300 mg CapsuleAlu/PVC Blister pack x 10's (Box of 30's and 100's) | Rx | Drugmaker's Laboratories, Inc.Philippines | Phil Pharmawealth, Inc. | DRP-803-05 | Jan 9, 2029 | |
SumigClindamycin (as phosphate) | 150 mg/mL Solution for Injection (I.M./I.V.)USP Type I clear glass ampoule in plastic tray x 2 mL (300 mg/2 mL; Box of 10’s) and 4 mL (600 mg/4 mL) (Box of 10's) | Rx | Kilitch Drugs (India) Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-10998-02 | Dec 31, 2026 | |
TG-MycinClindamycin (as hydrochloride) | 300 mg CapsuleBlister Pack x 10's (Box of 100's) | Rx | Scheele Laboratories Phils., Inc.Philippines | TGIF Pharmaceutical Trading Inc. | DRP-3708-04 | Mar 6, 2031 | |
TidactClindamycin (As Phosphate) | 10 mg/g GelAluminum Tube x 20 g (Box of 1’s) | Rx | Y.S.P Industries (M) SDN. BHDMalaysia | Yung Shin (Philippines), Inc. | DR-XY48093 | Sep 2, 2027 | |
TidactClindamycin (as Hydrochloride) | 150 mg CapsuleBlister foil x 10's Box of 100's | Rx | Y.S.P. Industries (M) Sdn BhdMalaysia | Yung Shin (Philippines), Inc. | DR-XY27623 | Jun 21, 2027 | |
TidactClindamycin (as Phosphate) | 150mg/mL Solution for Injection (I.M./I.V)Type I Clear Glass Vial x 2mL with Rubber Stopper and Yellow Flip-off Seal (Box of 10's) | Rx | Yung Shin Pharm. Ind. Co. Ltd. - Taichung Youth FactoryChina | YUNG SHIN (PHILIPPINES), INC | DRP-1039 | Oct 25, 2027 | |
TidactClindamycin (as hydrochloride) | 300 mg CapsuleAlu/Clear PVC Blister Pack x 10's (Box of 100's) | Rx | Y.S.P. Industries (M) Sdn. Bhd.Malaysia | Yung Shin (Philippines), Inc. | DRP-7835 | Feb 24, 2031 | |
TorodaClindamycin (as hydrochloride) | 300 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | J.M. Tolmann Laboratories, Inc.Philippines | Medirich Pharma Distribution Corp. | DR-XY41204 | Sep 11, 2027 | |
TorodaClindamycin (as hydrochloride) | 300 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | J.M. Tolmann Laboratories, Inc.Philippines | Medirich Pharma Distribution Corp. | DRP-15459 | Sep 11, 2027 | |
UnbrandedClindamycin phosphate | 20 mg / mL Topical SolutionClear HDPE Plastic Bottle x 60 mL (Box of 1's) | Rx | DS Cosmeceutical Manufacturing LaboratoryPhilippines | — | DRP-14857 | Sep 13, 2030 | |
UnbrandedClindamycin (As Hydrochloride) | 300 mg CapsuleAlu/PVDC/PVC Blister Pack x 10'S (Box of 100's) | Rx | Am-Europharma CorporationPhilippines | Am-Europharma Corporation | DRP-11765 | Apr 29, 2032 | |
VagilinClindamycin (as phosphate) | 100 mg Soft Gelatin Capsule (For Vaginal Use)Alu/ Clear PVC Blister Pack x 7's in a Box | Rx | Gelnova Laboratories (India) Pvt. Ltd.India | Scheeling, Inc.Importer: SRS Life Sciences Inc.Trader: SRS Pharmaceuticals Pvt. Ltd. | DRP-14430 | Jun 27, 2028 | |
Zindal 300Clindamycin (as hydrochloride) | 300 mg CapsuleBlister Pack x 10's (Box of 50's) | Rx | Lloyd Laboratories, Inc.Philippines | Trader: Heltker A.G. Corporation | DR-XY27641 | Jun 26, 2027 | |
ZynamycinClindamycin (as hydrochloride) | 300 mg CapsuleAlu/Alu Blister Pack x 10’s (Box of 10’s) | Rx | XL Laboratories Pvt. Ltd.India | Speed Cure PharmaImporter: Ambica International Corporation | DRP-1267-05 | Feb 9, 2031 | |
(no brand name)Clindamycin (as phosphate) | 10 mg/mL (1%) Topical SolutionOpaque White Bottle x 50 mL (Box of 1's) | Rx | Ashford Pharmaceutical Laboratories, Inc.Philippines | Trader: Time Machine Cosmetiques, Inc. | DR-XY34797 | Mar 6, 2029 | |
(no brand name)Clindamycin (as phosphate) | 150mg/mL Solution For InjectionType I Flint Glass Ampoule x 2 mL (Box of 10's); oule x 5 mL Type I Flint Glass Ampoule x 4 mL (net content) (Box of 5's) | Rx | Samrudh Pharmaceuticals Pvt. Ltd.India | I.E. Medica, Inc.Trader: Alvita Pharma Pvt. Ltd. | DRP-14164 | Jul 7, 2028 | |
(no brand name)Clindamycin (as hydrochloride) | 300 mg CapsuleAlu/Clear PVC/PVDC Blister Pack (60 GSM) x 10's (Box of 100's) | Rx | Lloyd Laboratories, Inc.Philippines | — | DRP-12245 | Sep 2, 2027 | |
(no brand name)Clindamycin (as Hydrochloride) | 300 mg CapsuleAluminum/PVDC/PVC Blister Pack x 10's (Box of 100's) | Rx | AM-Europharma CorporationPhilippines | United Laboratories Inc.Trader: RiteMED Phils., Inc. | DRP-12251 | Jul 1, 2027 | |
(no brand name)Clindamycin (as hydrochloride) | 300 mg CapsuleAlu/PVC Blister Pack x 10's (Box of 100's) | Rx | UNITED BIOTECH (P) LIMITEDIndia | Triple Tact Import & Export Corp. | DRP-14257 | Aug 7, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
The boxed warning is shown at the top of this page.
Warnings and precautions (US label) US FDA label
WARNINGS See BOXED WARNING. Clostridioides difficile -Associated Diarrhea Clostridioides difficile -associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including CLEOCIN PHOSPHATE, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.
C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibacterial drug use.
Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated.
Anaphylactic and Severe Hypersensitivity Reactions Anaphylactic shock and anaphylactic reactions have been reported (see ADVERSE REACTIONS). Severe hypersensitivity reactions, including acute myocardial ischemia with or without myocardial infarction, and severe skin reactions such as toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens‑Johnson syndrome (SJS), some with fatal outcome, have been reported (see ADVERSE REACTIONS).
In case of such an anaphylactic or severe hypersensitivity reaction, discontinue treatment permanently and institute appropriate therapy. A careful inquiry should be made concerning previous sensitivities to drugs and other allergens. Benzyl Alcohol Toxicity in Neonates ("Gasping Syndrome") This product contains benzyl alcohol as a preservative.
The administration of intravenous solutions containing the preservative benzyl alcohol has been associated with the "gasping syndrome", and death in neonates. Symptoms include a striking onset of gasping respiration, hypotension, bradycardia, and cardiovascular collapse. Although the normal therapeutic dose of this product delivers amounts of benzyl alcohol that are substantially lower than those reported in association with the "gasping syndrome", the minimum amount of benzyl alcohol at which toxicity may occur is not known and total daily benzyl alcohol exposure may be increased by concomitant medications.
The risk of benzyl alcohol toxicity depends on the quantity administered and the liver and kidneys' capacity to detoxify the chemical. Premature and low birth weight infants may be more likely to develop toxicity. Nephrotoxicity Clindamycin is potentially nephrotoxic and cases with acute kidney injury have been reported.
Consider monitoring of renal function particularly in patients with pre-existing renal dysfunction or those taking concomitant nephrotoxic drugs. In case of acute kidney injury, discontinue CLEOCIN PHOSPHATE when no other etiology is identified. Usage in Meningitis Since clindamycin does not diffuse adequately into the cerebrospinal fluid, the drug should not be used in the treatment of meningitis.
Drug interactions
Drug interactions (US label) US FDA label
Drug Interactions Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents. Clindamycin is metabolized predominantly by CYP3A4, and to a lesser extent by CYP3A5, to the major metabolite clindamycin sulfoxide and minor metabolite N-desmethylclindamycin.
Therefore, inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin. In the presence of strong CYP3A4 inhibitors, monitor for adverse reactions. In the presence of strong CYP3A4 inducers such as rifampicin, monitor for loss of effectiveness.
In vitro studies indicate that clindamycin does not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2E1 or CYP2D6 and only moderately inhibits CYP3A4.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Metabolism In vitro studies in human liver and intestinal microsomes indicated that clindamycin is predominantly metabolized by Cytochrome P450 3A4 (CYP3A4), with minor contribution from CYP3A5, to form clindamycin sulfoxide and a minor metabolite, N-desmethylclindamycin.
Clindamycin is metabolized predominantly by CYP3A4, and to a lesser extent by CYP3A5, to the major metabolite clindamycin sulfoxide and minor metabolite N-desmethylclindamycin.
Therefore, inhibitors of CYP3A4 and CYP3A5 may increase plasma concentrations of clindamycin and inducers of these isoenzymes may reduce plasma concentrations of clindamycin.
In the presence of strong CYP3A4 inhibitors, monitor for adverse reactions.
In the presence of strong CYP3A4 inducers such as rifampicin, monitor for loss of effectiveness.
In vitro studies indicate that clindamycin does not inhibit CYP1A2, CYP2C9, CYP2C19, CYP2E1 or CYP2D6 and only moderately inhibits CYP3A4.
Adverse reactions
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS The following reactions have been reported with the use of clindamycin. Infections and Infestations: Clostridioides difficile colitis Gastrointestinal: Antibacterial drug-associated colitis (see WARNINGS), pseudomembranous colitis, abdominal pain, nausea, and vomiting. The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment (see WARNINGS).
An unpleasant or metallic taste has been reported after intravenous administration of the higher doses of clindamycin phosphate. Hypersensitivity Reactions: Maculopapular rash and urticaria have been observed during drug therapy. Generalized mild to moderate morbilliform-like skin rashes are the most frequently reported of all adverse reactions.
Severe skin reactions such as toxic epidermal necrolysis, some with fatal outcome, have been reported (see WARNINGS). Cases of acute generalized exanthematous pustulosis (AGEP), erythema multiforme, some resembling Stevens-Johnson syndrome, have been associated with clindamycin. Anaphylactic shock, anaphylactic reaction, hypersensitivity, and acute myocardial ischemia with or without myocardial infarction occurring as part of an allergic reaction have also been reported (see WARNINGS).
Cutaneous vasculitis and symmetrical drug-related intertriginous and flexural exanthema have also been reported. Skin and Mucous Membranes: Pruritus, vaginitis, angioedema and rare instances of exfoliative dermatitis have been reported (see Hypersensitivity Reactions). Liver: Jaundice and abnormalities in liver function tests have been observed during clindamycin therapy.
Renal: Acute kidney injury (see WARNINGS). Hematopoietic: Transient neutropenia (leukopenia) and eosinophilia have been reported. Reports of agranulocytosis and thrombocytopenia have been made. No direct etiologic relationship to concurrent clindamycin therapy could be made in any of the foregoing. Immune System: Drug reaction with eosinophilia and systemic symptoms (DRESS) cases have been reported.
Local Reactions: Injection site irritation, pain, induration and sterile abscess have been reported after intramuscular injection and thrombophlebitis after intravenous infusion. Reactions can be minimized or avoided by giving deep intramuscular injections and avoiding prolonged use of indwelling intravenous catheters. Musculoskeletal: Polyarthritis cases have been reported.
Cardiovascular: Cardiopulmonary arrest and hypotension have been reported following too rapid intravenous administration (see DOSAGE AND ADMINISTRATION).
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy Teratogenic effects In clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters, has not been associated with an increased frequency of congenital abnormalities. Clindamycin should be used during the first trimester of pregnancy only if clearly needed.
There are no adequate and well-controlled studies in pregnant women during the first trimester of pregnancy. Because animal reproduction studies are not always predictive of the human response, this drug should be used during pregnancy only if clearly needed. Reproduction studies performed in rats and mice using oral doses of clindamycin up to 600 mg/kg/day (2.1 and 1.1 times the highest recommended adult human dose based on mg/m 2, respectively) or subcutaneous doses of clindamycin up to 250 mg/kg/day (0.9 and 0.5 times the highest recommended adult human dose based on mg/m 2, respectively) revealed no evidence of teratogenicity.
CLEOCIN PHOSPHATE Sterile Solution contains benzyl alcohol. Benzyl alcohol can cross the placenta (See WARNINGS).
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers Limited published data based on breast milk sampling reports that clindamycin appears in human breast milk in the range of less than 0.5 to 3.8 mcg/mL at dosages of 150 mg orally to 600 mg intravenously. Clindamycin has the potential to cause adverse effects on the breast-fed infant's gastrointestinal flora.
If oral or intravenous clindamycin is required by a nursing mother, it is not a reason to discontinue breastfeeding, but an alternate drug may be preferred. Monitor the breast-fed infant for possible adverse effects on the gastrointestinal flora, such as diarrhea, candidiasis (thrush, diaper rash) or rarely, blood in the stool indicating possible antibacterial drug-associated colitis.
The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for clindamycin and any potential adverse effects on the breast-fed child from clindamycin or from the underlying maternal condition.
Mechanism of action
Mechanism of Action Clindamycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome. Clindamycin is bacteriostatic.
US FDA labelPharmacokinetics
Excretion Biologically inactive clindamycin phosphate disappears from the serum with 6 minutes of the average elimination half-life; however, the average serum elimination half-life of active clindamycin is about 3 hours in adults and 2½ hours in pediatric patients.
Specific Populations Patients with Renal/Hepatic Impairment The elimination half-life of clindamycin is increased slightly in patients with markedly reduced renal or hepatic function.
Geriatric Patients Pharmacokinetic studies in elderly volunteers (61–79 years) and younger adults (18–39 years) indicate that age alone does not alter clindamycin pharmacokinetics (clearance, elimination half-life, volume of distribution, and area under the serum concentration-time curve) after IV administration of clindamycin phosphate.
After oral administration of clindamycin hydrochloride, the average elimination half-life is increased to approximately 4.0 hours (range 3.4–5.1 h) in the elderly, compared to 3.2 hours (range 2.1–4.2 h) in younger adults.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY Distribution Biologically inactive clindamycin phosphate is converted to active clindamycin. By the end of short-term intravenous infusion, peak serum concentrations of active clindamycin are reached. After intramuscular injection of clindamycin phosphate, peak concentrations of active clindamycin are reached within 3 hours in adults and 1 hour in pediatric patients.
Serum concentrations of clindamycin can be maintained above the in vitro minimum inhibitory concentrations for most indicated organisms by administration of clindamycin phosphate every 8 to 12 hours in adults and every 6 to 8 hours in pediatric patients, or by continuous intravenous infusion. An equilibrium state is reached by the third dose.
No significant concentrations of clindamycin are attained in the cerebrospinal fluid even in the presence of inflamed meninges. Metabolism In vitro studies in human liver and intestinal microsomes indicated that clindamycin is predominantly metabolized by Cytochrome P450 3A4 (CYP3A4), with minor contribution from CYP3A5, to form clindamycin sulfoxide and a minor metabolite, N-desmethylclindamycin.
Excretion Biologically inactive clindamycin phosphate disappears from the serum with 6 minutes of the average elimination half-life; however, the average serum elimination half-life of active clindamycin is about 3 hours in adults and 2½ hours in pediatric patients. Specific Populations Patients with Renal/Hepatic Impairment The elimination half-life of clindamycin is increased slightly in patients with markedly reduced renal or hepatic function.
Hemodialysis and peritoneal dialysis are not effective in removing clindamycin from the serum. Dosage schedules do not need to be modified in patients with renal or hepatic disease. Geriatric Patients Pharmacokinetic studies in elderly volunteers (61–79 years) and younger adults (18–39 years) indicate that age alone does not alter clindamycin pharmacokinetics (clearance, elimination half-life, volume of distribution, and area under the serum concentration-time curve) after IV administration of clindamycin phosphate.
After oral administration of clindamycin hydrochloride, the average elimination half-life is increased to approximately 4.0 hours (range 3.4–5.1 h) in the elderly, compared to 3.2 hours (range 2.1–4.2 h) in younger adults. The extent of absorption, however, is not different between age groups and no dosage alteration is necessary for the elderly with normal hepatic function and normal (age-adjusted) renal function 1.
Pharmacokinetics in Pediatric Patients with PMA ≤32 weeks, or >32 to ≤40 weeks Systemic clearance (CL) in premature infants increases with increases in body weight (kg) and post-menstrual age (PMA). The dosing regimens for pediatric patients ≤32 weeks PMA (5 mg/kg) and >32 to ≤40 weeks PMA (7 mg/kg), both administered intravenously every 8 hours, achieve exposures comparable to therapeutic exposures in adults (weighing 70 kg) administered clindamycin 600 mg every 8 hours (Table 1).
Table 1: Predicted Drug Exposure (Mean ± SD) of Clindamycin in Adults and in Pediatric Patients with PMA ≤32 weeks, or >32 to ≤40 weeks Age Adult (70 kg) PMA ≤32 weeks PMA>32 – ≤40 weeks PMA: post-menstrual age; AUC ss,0–8 hour: area under the concentration-time curve during a dosing interval at steady state; C max,ss: maximum drug concentration at steady state; C min,ss: minimum or trough drug concentration at steady state. Dose (every 8 hours) 600 mg 5 mg/kg 7 mg/kg AUC ss,0–8 hour (mcg∙h/mL) 50.5 (30.95) 52.5 (17.0) 55.9 (23.55) C max,ss (mcg/mL) 12.0 (3.49) 9.0 (2.02) 10.5 (2.79) C min,ss (mcg/mL) 3.1 (3.34) 4.6 (2.00) 4.4 (2.77) Obese Pediatric Patients Aged 2 to Less than 18 Years and Obese Adults Aged 18 to 20 Years An analysis of pharmacokinetic data in obese pediatric patients aged 2 to less than 18 years and obese adults aged 18 to 20 years demonstrated that clindamycin clearance and volume of distribution, normalized by total body weight, are comparable regardless of obesity.
Microbiology Mechanism of Action Clindamycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome. Clindamycin is bacteriostatic. Resistance Resistance to clindamycin is most often caused by modification of specific bases of the 23S ribosomal RNA. Cross-resistance between clindamycin and lincomycin is complete.
Because the binding sites for these antibacterial drugs overlap, cross-resistance is sometimes observed among lincosamides, macrolides and streptogramin B. Macrolide-inducible resistance to clindamycin occurs in some isolates of macrolide-resistant bacteria. Macrolide-resistant isolates of staphylococci and beta-hemolytic streptococci should be screened for induction of clindamycin resistance using the D-zone test.
Antimicrobial Activity Clindamycin has been shown to be active against most of the isolates of the following microorganisms, both in vitro and in clinical infections (see INDICATIONS AND USAGE): Gram-positive bacteria Staphylococcus aureus (methicillin-susceptible strains) Streptococcus pneumoniae (penicillin-susceptible strains) Streptococcus pyogenes Anaerobic bacteria Clostridium perfringens Fusobacterium necrophorum Fusobacterium nucleatum Peptostreptococcus anaerobius Prevotella melaninogenica The following in vitro data are available, but their clinical significance is unknown. At least 90 percent of the following bacteria exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for clindamycin against isolates of a similar genus or organism group.
However, the efficacy of clindamycin in treating clinical infections due to these bacteria has not been established in adequate and well-controlled clinical trials. Gram-positive bacteria Staphylococcus epidermidis (methicillin-susceptible strains) Streptococcus agalactiae Streptococcus anginosus Streptococcus mitis Streptococcus oralis Anaerobic bacteria Actinomyces israelii Clostridium clostridioforme Eggerthella lenta Finegoldia (Peptostreptococcus) magna Micromonas (Peptostreptococcus) micros Prevotella bivia Prevotella intermedia Cutibacterium acnes Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Clindamycin 75 mg/5 mL, 60 mL Suspension | ₱108.80–₱490.00Reference ₱108.80 | per unit | DPRI procurement range |
| Clindamycin 150 mg Capsule | ₱2.45–₱6.80Reference ₱2.75 | per capsule | DPRI procurement range |
| Clindamycin 150 mg/mL, 2 mL Ampule | ₱77.32–₱565.00Reference ₱93.94 | per ampule | DPRI procurement range |
| Clindamycin 150 mg/mL, 4 mL Ampule | ₱39.50–₱188.00Reference ₱73.00 | per ampule | DPRI procurement range |
| Clindamycin 300 mg Capsule | ₱4.00–₱37.00Reference ₱5.35 | per capsule | DPRI procurement range |
| 75 mg/5 mL (as palmitate hydrochloride) granules for suspension in 60 mL | ₱568.75 | per unit | PhilHealth GAMOT fixed fee |
| 150 mg (as hydrochloride) capsule | ₱14.75 | per capsule | PhilHealth GAMOT fixed fee |
| 300 mg (as hydrochloride) capsule | ₱29.75 | per capsule | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Clindamycin |
| PNF listing | Oral: 150 mg and 300 mg capsule (as hydrochloride) |
| PNF listing | Oral: 75 mg/5 mL granules for suspension, 60 mL (as palmitate hydrochloride) |
| PNF listing | Inj.: 150 mg/mL, 2 mL ampul/vial and 4 mL ampul (IM, IV) (as phosphate) |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. Cleocin Phosphate · Pharmacia & Upjohn Company LLC [US FDA-approved label, version 15, May 13, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0a2eff7-b7de-42fe-8e5a-0cfbed38bb4b
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .